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A B S T R A C T
The extracellular domain of the human epidermal growth factor receptor 2 (HER2-ECD) is a protein breast
cancer biomarker. Its quantification in peripheral blood could provide an important contribution to diagnostics
and patient follow-up. In this work an electrochemical molecularly imprinted polymer (MIP) sensor for the
quantification of HER2-ECD was developed. The MIP was electropolymerized by cyclic voltammetry using a
solution containing phenol and HER2-ECD on a screen-printed gold electrode (AuSPE). The sensor was char-
acterized by cyclic voltammetry and electrochemical impedance spectroscopy. The analysis of HER2-ECD was
performed by differential pulse voltammetry using ([Fe(CN)6]3−/4− as redox probe. The linear range was es-
tablished in the concentration interval from 10 to 70 ng/mL HER2-ECD, with a limit of detection of 1.6 ng/L and
a limit of quantification of 5.2 ng/mL. Through the analysis of other protein biomarkers, the MIP sensor was
found to be selective. Furthermore, these proteins did not interfere in the analysis of the selected biomarker. The
developed sensor was used for the analysis of spiked human serum samples, providing adequate recovery values
and precise results. The outcomes of this study indicate that the developed MIP sensor could be useful in the non-
invasive analysis of HER2-ECD in breast cancer patients.
1. Introduction
Breast cancer is the most common neoplasia among women [1].
Although breast cancer cases contribute to about 25% of cancer in-
cidence worldwide, it is one of the leading cancer related mortality in
women [2]. To date, an exponential increase of this oncological disease
in women has been observed, and according to the data collected by the
World Health Organization (WHO) in 2012, breast cancer was the
second cause of cancer death in the more developed regions [3].
The effectiveness of mammography screening programs and the
improvement in treatment and follow-up have been able to lower the
mortality rate and thus, it is now lower than the incidence rate [4,5].
Therefore, early detection of cancer has a crucial role and is one of the
major factors that contributes to increase not only the survival rates,
but also to improve a successful clinical prognosis. Thus, a substantial
reduction of effective treatment cost and time and an increase in the life
expectancy can be attained [6,7]. Because of the inherent limitations of
mammography screening, it should be complemented with additional
clinical tests to avoid misdiagnosis or overdiagnosis [8]. This screening
is usually not performed in young women (≤ 45 years) because of its
low sensitivity, leading to poor early diagnosis [9].
For early breast cancer detection and diagnosis, it is important to
highlight that cellular changes at the protein level are considered po-
tential tumor (bio)markers which complement screening methods, such
as MRI, sonography and mammography [10,11]. A biomarker is de-
fined by the National Cancer Institute as “a biological molecule found in
blood, other body fluids, or tissues that is sign of a normal or abnormal
process or of a condition disease” [12]. Thus, biomarkers allow the
detection of specific diseases and the selection of effective interven-
tions, improving the balance between benefit and harm of breast cancer
screening [13]. Besides their detection in blood, breast cancer bio-
markers can also be found in other biological fluids, including sputum
and urine [14]. For the analysis of biological fluids non-invasive
methodologies to revitalize early detection are required [7]. A simple
non-invasive blood screening test could detect and monitor cancer
progression and reduce the suffering of patients [15]. However, there
are few blood-based biomarkers with clinical use in breast cancer de-
tection [16].
The most reported breast cancer protein biomarkers are the Human
Epidermal Growth Factor Receptor 2 (HER2), Cancer Antigen 15-3 (CA
15-3) and Carcinoembryonic Antigen (CEA) [15,16]. Of these proteins,
HER2 is already established as a notably tissue marker [15], whose
characterization is usually made in primary or metastatic tumors and
has mainly been used as a target in immunotherapy [17,18]. Although
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this treatment is only effective in patients with an excess of receptor
levels [14]. The protein has three domains: an extracellular domain
(ECD) with similarities to other EGFRs, a short hydrophobic trans-
membrane region and an intracellular domain with tyrosine kinase
activity. The ECD can be cleaved from the cell surface by matrix me-
talloproteases generating soluble truncated HER2 molecules, whose
concentration can be measured in the serum fraction of the blood [19].
Currently, the established diagnostic tests to determine the expres-
sion of HER2 are based on invasive methods such as biopsies, using
immunohistochemistry (IHC) and fluorescent in situ hybridization
(FISH) methods [19,20]. However, both IHC and FISH techniques are
limited to semiquantitative results, and are expensive and complex
procedures, that are time consuming and require specially trained
personnel to carry out the multi-step procedures [20,21] and a high-
quality tissue sample [22,23].
The detection of HER2-ECD in blood or serum is not a routine
practice [15]. However, besides its diagnostic importance, this bio-
marker can be a prognostic factor, with better results than tissue biopsy
analysis [24,25]. More importantly, the protein level measurement has
the potential of monitoring the course of the disease and the response of
patients to treatment [14]. Considering that HER2-ECD in serum is
generally quantified using an enzyme-linked immunosorbent assay
(ELISA) and that the approved cut-off concentration is 15 ng/mL, ELISA
assays are not sufficiently sensitive in the prognostic detection. This is
then susceptible to produce false results, highlighting the need for the
development of a convenient, cost-effective and ultrasensitive method
that minimizes the disadvantages of conventional methodologies
[15,26].
Electrochemical (bio)sensors have attracted considerable interest
because of their particular properties such as high sensitivity and se-
lectivity. These sensors are easy to use, provide fast responses and are
cheap, disposable and capable of multi-analyte testing [8,21,27].
Among the several strategies to increase the selectivity of electro-
chemical sensors, molecularly imprinted polymers (MIP) can be used.
MIPs offer the ability to mimic the highly selective bio-recognition
characteristics of enzymes and antibodies and have physical and che-
mical resistances to degrading external factors, which make them pro-
mising analytical tools for the construction of biomimetic recognition
systems [27,28]. Besides the success in the imprinting of small mole-
cules, the imprinting of macromolecules (such as proteins) is in con-
stant development, however it has some inherent difficulties, including
size, conformation flexibility and solubility [29,30]. Electro-
polymerization of functional electroactive monomers directly on the
transducer surface has proven to be a good option for protein im-
printing because it allows polymerization in aqueous solutions, easy
control and production of thin polymeric films. In this process the se-
lected functional monomers are polymerized around the template
[31,32]. Recently electrochemical MIP-based sensors have been applied
as promising tools for early breast cancer detection. In a previous work
developed by our team [33] a MIP-sensor for the detection of the
protein breast cancer biomarker CA 15-3 was constructed based on
direct surface imprinting of the protein, using 2-aminophenol as the
monomer, on a screen-printed gold electrode (AuSPE). The detection
limit of this sensor was 1.5 U mL−1 which is well below the used cut-off
value in clinical practice for this biomarker (25 U mL−1).
In the present study a selective voltammetric MIP-sensor for the
determination of HER2-ECD was developed. The imprinting of the
cancer biomarker on AuSPE was performed by electropolymerization of
a solution containing phenol (monomer) and HER2-ECD. The applic-
ability of the sensor was tested by analyzing spiked human serum
samples.
2. Experimental
2.1. Reagents
Recombinant HER2-ECD was obtained from Sino Biological Inc.
Working solutions of HER2-ECD were prepared daily in phosphate
buffer (0.1M, pH 7.4) and stored at 4 °C. Human serum (from male AB
plasma) was obtained from Sigma-Aldrich. For interference studies, CA
15-3, obtained from MyBioSource, and Cystatin C, obtained from R&D
Systems were used.
Phenol (> 99.5%) and acetic acid (≥99.5%) were purchased from
Merck and Sodium dodecyl sulphate (SDS) from Panreac. Other com-
mercially available reagents were used without further purification.
Ultra-pure water (resistivity= 18.2MΩ.cm) obtained from a Millipore
(Simplicity 185) water purification system was used throughout the
work. The phosphate buffer (0.1M, pH 7.4) was prepared with KH2PO4
and K2HPO4 (Riedel-de-Haën).
2.2. Apparatus
Electrochemical measurements (cyclic voltammetry (CV) and dif-
ferential pulse voltammetry (DPV)) were performed using a Metrohm
Autolab PGSTAT 204 potentiostat/galvanostat controlled by NOVA
1.10 software. Electrochemical impedance spectroscopy (EIS) was per-
formed using a Metrohm Autolab PGSTAT 128 N potentiostat/galva-
nostat controlled by NOVA 1.6 software. Screen-printed gold electrodes
(Dropsens, DRP C223 AT) composed of gold working (d=1.6mm) and
auxiliary electrodes, and a silver pseudo reference electrode were used.
The specific connector (DRP-CAC) to interface the AuSPE and the po-
tentiostat/galvanostat was supplied by DropSens.
2.3. Sensor fabrication
The stepwise construction process is illustrated in Fig. 1. Prior to
their use the AuSPEs were rinsed with distilled water and activated with
0.1 M H2SO4 by CV (potential range: -0.2 V to +1.3 V, scan rate:
100mV/s).
In the optimized construction of the MIP-sensor, 40 μL of the poly-
merization solution (20mM phenol, 15 μg/mL HER2-ECD in phosphate
buffer) was placed on the AuSPE and electropolymerization was carried
out by CV in the potential range between 0.2 V and +1.0 V at a scan
rate of 100mV/s, during 20 cycles. A non-imprinted polymer electrode
(NIP) was prepared using the same experimental conditions but ex-
cluding HER2-ECD from the polymerization solution. The electrodes
were then rinsed with ultra-pure water and 40 μL of an SDS (0.5%) and
acetic acid (0.5%) solution was placed on the sensor surface for 30min.
After this step, ultra-pure water was placed on the sensor for 10min,
followed by phosphate buffer for an additional 5min. In this process,
HER2-ECD is extracted from the polymeric films and cavities are
formed that are complimentary to the protein’s shape, size and func-
tionality.
2.4. Electrochemical detection
The interactions between HER2-ECD and the MIP and NIP were
indirectly measured using [Fe(CN)6]3−/4− (2 mM in 0.1M phosphate
buffer, pH 7.4) as redox probe. CV, DPV and EIS were used to char-
acterize the sensors in the different optimization and construction steps.
In the optimized assay to detect the breast cancer protein, the sensors
were incubated with 20 μL of a HER2-ECD solution during 7min and
then, between each protein incubation, washed with ultra-pure water
and dried. The signal was recorded using CV (-0.1 V to +0.6 V at a scan
rate of 50mV/s) and DPV (-0.2 V to +0.8 V using a pulse amplitude of
25mV). In the EIS measurements, a sinusoidal signal with a 10-mV
amplitude and a potential of +0.2 V was applied (frequency range
between 0.1 and 10,000 Hz with 50 frequencies distributed
logarithmically). Randles equivalent electrical circuit was used as a
model by fitting the Nyquist plot as experimental EIS data. All mea-
surements were performed at room temperature.
2.5. Sample preparation
The human serum was first diluted to 50% with 0.1 M phosphate
buffer (pH 7.4), and then spiked with different HER2-ECD concentra-
tions and analysed without further treatment. The electrochemical
measurements were performed according to the above-mentioned
conditions.
3. Results and discussion
3.1. MIP sensor preparation
In this work, the molecular imprinting of HER2-ECD was performed
by electropolymerization of a solution containing 20mM phenol and
15 μg/mL HER2-ECD in phosphate buffer (pH 7.4) on the surface of
AuSPEs. Electropolymerization was performed by 20 CV scans between
-0.2 and +1.0 V (Fig. 2A), forming a polyphenol film with entrapped
HER2-ECD molecules. The typical irreversible redox process of phenol
was observed and an increase of the number of scans reduces the oxi-
dation current intensity, indicating that the amount of polymer formed
on the electrode surface increases because polyphenol is a non-con-
ducting polymer that hinders electron transfer to the electrode surface.
A NIP electrode was also prepared using the same conditions, but
without the inclusion of HER2-ECD in the polymerization solution
(Fig. 2B). As expected, differences between the film growths of the NIP
and MIP were observed (Fig. 2C). In the first polymerization cycle the
oxidation peak current intensity observed in the MIP process was lower
than the one observed in the NIP process. This is mainly due to the
interaction between HER2-ECD and phenol.
After the preparation of the polymeric film, a 2mM [Fe(CN)6]3−/4−
solution was analysed by DPV with the NIP and MIP sensors. As can be
observed in Fig. 3 there is a significant difference between the signals
obtained by both sensors. The oxidation peak current intensity of the
redox probe obtained with the NIP was higher than the peak current for
and MIP after polymerization. There is a major block in the signal of
MIP. This result can be related to the entrapment of the HER2-ECD
molecules. After the polymerization step the HER2-ECD molecules were
removed from the MIP to assure that the binding cavities com-
plementary to the molecular shape, size and functionality of HER2-ECD
inside the polymeric film are created. The extraction conditions were
optimised using the following extraction solutions: water, hydrochloric
acid (0.1 M) and methanol (50:50, v/v) mixture, guanidine (0.5 M), SDS
(0.5%) and acetic acid (0.5%). Furthermore, the extraction time (30, 60
and 90min) was also studied. It was found that the most adequate
extraction procedure was achieved using an SDS (0.5%) and acetic acid
(0.5%) solution during 30min. After extraction, a 2mM [Fe(CN)6]3−/
4− solution was again analysed by DPV. As expected, the obtained peak
current intensity increased when compared to the peak current in-
tensity obtained after polymerization (Fig. 3), indicating the efficient
removal of the HER2-ECD molecule template and the formation of the
Fig. 1. Schematic illustration of the construction and operation of the MIP/AuSPE.
Fig. 2. CV voltammograms recorded during the electropolymerization on the AuSPE of (A) the MIP (20 mM phenol and 15 μg/mL HER2-ECD, in 0.1M phosphate
buffer pH 7.4 (20 cycles)), (B) NIP and (C) the NIP and MIP (1st and 20th scan).
specific cavities in the film.
3.2. Optimization of polymerization conditions
The electropolymerization process was optimised to obtain the
highest signal for the redox probe in the DPV analysis. The following
parameters of the process were studied: the number of CV cycles and
the phenol and HER2-ECD concentrations (Fig. 4). The results are
presented as the difference (Δip) between the peak current intensity
after the initial extraction of HER2-ECD and the peak current intensity
after the subsequent incubation with HER2-ECD.
In electropolymerization it is possible to control the polymer
thickness by controlling the number of potential cycles. Therefore,
different number of CV cycles were tested (10, 20, 30 and 40) (Fig. 3A).
As can be seen in Fig. 4A, the Δip increased from 10 to 20 cycles, fol-
lowed by a decrease from 20 to 40 cycles. This decrease is due to the
formation of a thicker (non-conductive) polymer which hinders elec-
tron transfer and/or diffusion of the redox probe to the electrode sur-
face, leading to lower Δip values. For this reason, 20 polymerization
cycles were chosen for the subsequent optimization steps.
Different concentrations of the monomer (phenol) in the poly-
merization solution were tested (1.0, 2.5, 5.0, 10 and 20mM) (Fig. 4B):
a continuous decrease of Δip between 1.0 and 5.0 mM and a continuous,
but less accentuated, increase of Δip between 5.0 and 20mM were
observed. Because only a slight increase of Δip between 10 and 20mM
of phenol was seen, higher phenol concentrations were not tested and
20mM was chosen for further studies.
The optimal concentration of HER2-ECD in the polymerization
solution was found to be 15 μg/mL (Fig. 3C): an increase of Δip between
3 and 15 μg/mL was recorded, after which Δip decreased. For the lower
concentrations, lower amounts of the protein were entrapped in
polymer, leading to less cavities and lower Δip values. On the other
hand, when the concentration was higher than 15 μg/mL the Δip value
decreased, which was probably due to the difficulty of extracting the
protein from the polymer matrix, which also led to a lower number of
formed cavities and a lower Δip value.
After extraction, the inclusion of HER2-ECD in the MIP is obviously
influenced by the incubation time. Therefore, the incubation time as
also tested. It was found that 7min incubation period was provided
higher Δip values.
3.3. Characterization of the NIP- and MIP sensors
Throughout the construction processes the sensors were char-
acterised by CV and EIS using 2mM [Fe(CN)6]3−/4− . The results ob-
tained with the bare electrode and the modified electrodes are shown in
Fig. 5. With the bare gold electrode, a typical CV voltammogram of the
redox probe was obtained, observing its well-defined reversible redox
peaks. After polymerization, an expected decrease of the current re-
sponse was registered with the NIP-AuSPE and MIP-AuSPE, which is
characteristic for a passivated electrode surface. However, with the
MIP-AuSPE the peak current intensities were slightly higher than the
ones obtained with the NIP-AuSPE. This is probably due to the en-
trapment of protein in the polymeric film. After extraction, when the
HER2-ECD molecules were removed from the MIP, the ip increased
because of the unoccupied cavities that enhance the diffusion of [Fe
(CN)6]3−/4− to the electrode surface and promote its redox behaviour,
confirming the efficient removal of the template and the effectiveness of
the MIP. When the MIP-AuSPE was incubated with an HER2-ECD so-
lution, for 7min, the ip once again decreased. This indicates that HER2-
ECD occupied some of the previously formed cavities, preventing the
diffusion and the redox reaction of [Fe(CN)6]3−/4− . This also proves
the ability of the MIP-sensor to incorporate HER2-ECD molecules after
incubation.
Similar behaviours were observed in the EIS analyses. The semi-
circle of the Nyquist diagram for higher frequencies corresponds to the
electron transfer process while the linear part of the lower frequency
corresponds to diffusion. In Fig. 5 it can be observed a diffusion limited
process with fast electron transfer kinetics for the bare AuSPE. As ex-
pected, after polymerization there was a high increase of the impedance
of NIP and MIP and the surface was highly resistant to electron transfer
due to the formation of the non-conducting polymer films. For MIP the
surface is more resistant than NIP which can be explained by the en-
trapment of the protein. After protein extraction a high decrease of the
impedance was observed due to the formation of cavities and then
improving the diffusion of [Fe(CN)6]3−/4− through the polymer which
facilitates the electron transfer electrons. Finally, after the incubation of
Fig. 3. DPV voltammograms of 2mM [Fe(CN)6]3−/4− (in 0.1M phosphate
buffer, pH 7.4) of NIP, MIP sensor after polymerization and MIP after the ex-
traction of HER2-ECD.
Fig. 4. Results obtained in the optimization of the polymerization process. (A) Number of CV cycles; (B) phenol concentration; and (C) HER2-ECD concentration.
the protein an increase of the semicircle as registered. This indicates the
ability of the MIP sensor to rebind to the protein.
3.4. Analytical response
Under the optimized conditions, the relationship between Δip and
HER2-ECD concentration was evaluated in the range of 10–70 ng/mL
using the MIP-AuSPE (Fig. 6). A linear relationship was found between
10 and 70 ng/mL and the linear regression equation was: Δip
(A)= 1.259×10−8 [HER2-ECD] (ng/mL) + 1.490× 10−8
(R= 0.997). The limits of detection (LOD) and quantification (LOQ)
were 1.6 ng/ml and 5.2 ng/mL, respectively. These limits were calcu-
lated using the following equations: LOD=3 s/m and LOQ=10 s/m,
where "s" is the standard deviation of the intercept and "m" is the slope
of the calibration line.
The intra-day and inter-electrode precision was evaluated by ana-
lyzing 7 HER2-ECD concentrations in the linear range, obtaining an
average relative standard deviation of 15%.
3.5. Selectivity studies
To verify the selectivity of the sensor, other serum proteins were
analysed with the sensor: CA 15-3 (a breast cancer biomarker protein)
and Cystatin C (an important renal biomarker protein). These proteins
were chosen because they may also be present in serum samples.
Concentrations of 30 U/mL for CA 15-3 and 550 ng/mL for Cystatin C
were used because these are respectively, the cut-off value for disease
determination and the average value for healthy adults. In addition,
parallel interference tests were carried out by mixing these proteins
with HER2-ECD (15 ng/mL). All the solutions were prepared in human
serum and both the NIP- and MIP-sensor were tested. As can be con-
firmed in Fig. 7, the obtained Δip for the MIP-sensor after incubation
with HER2-ECD shows the highest value, demonstrating the effective
imprinting process. When a CA 15-3 solution was analysed, the Δip
obtained with the MIP-sensor was about half (51%) of the Δip for HER2-
ECD and was identical to the NIP-sensor. For cystatin C, Δip was only
about a third (29%) of the signal obtained when HER2-ECD was used.
This indicates that the MIP-sensor is selective for HER2-ECD. Further-
more, the results obtained (95% of the original Δip) when HER2-ECD is
incubated simultaneously with the other proteins show that these
proteins do not interfere in the analysis.
Fig. 5. Characterization of the step by step construction of the MIP/AuSPE sensor. (A) CV voltammograms and (B) EIS Nyquist diagrams in 2mM [Fe(CN)6)]3−/4−
and 0.1M phosphate buffer pH 7.
Fig. 6. Variation of the peak current intensity for MIP sensor with the con-
centration and DPV voltammograms obtained for MIP sensor after incubation
with different protein concentrations in the range 10–70 ng/mL. ip0 is the peak
current before incubation, ipc is the peak current after incubation in different
protein concentrations. Fig. 7. Selectivity and interference studies.
3.6. Detection of HER2-ECD breast cancer protein in biological samples
To validate the application of the MIP-sensor for HER2-ECD detec-
tion and to evaluate the possibility for practical and clinical applica-
tions, the sensor was tested using human serum samples. The samples
were spiked with three different protein concentrations (10, 30 and
50 ng/mL) and the analyses were carried out using the standard addi-
tion method. The obtained recovery values (Table 1) were between 80
and 90% and the RSD values were less than 10.2%, demonstrating that
the MIP-sensor provides accurate and precise results.
4. Conclusion
A selective molecularly imprinted polymer sensor for the detection
of the breast cancer biomarker HER2-ECD was developed in this work.
The sensor showed a linear concentration range from 10 to 70 ng/L,
with a limit of detection of 1.6 ng/L. This limit is well below the es-
tablished cut-off value. The developed methodology provides a simple,
easy-to-operate, economical and selective analysis. Furthermore, the
results of the analysis of the biomarker in human serum as well as the
possibility for fast detection and decentralized analysis, indicate that
this MIP-sensor could be of great promise for early clinical control tests
and patient follow-up.
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